740results about "Spray delivery" patented technology

The invention belongs to the technical field of bionic nano-drugs, and particularly relates to a bionic vesicle preparation as well as a preparation method and application thereof. The bionic vesicle preparation disclosed by the invention is prepared from the following raw materials: mesenchymal stem cell outer vesicles, nintedanib and DSPE-PEG-HA (hyaluronic acid modified pegylated phospholipid); the nintedanib is loaded in the mesenchymal stem cell outer vesicle, and the DSPE-PEG-HA is coupled to the surface of the mesenchymal stem cell outer vesicle. The bionic vesicle preparation disclosed by the invention can be used for directly delivering a drug to a pulmonary fibrosis injury part through inhalation type drug delivery, and acting on a focus part at a higher local concentration, meanwhile, the exposure of the drug in whole-body circulation is remarkably reduced, the occurrence of side effects is reduced, and the specific targeting intervention and regulation on fibroblasts are realized.

Provided are methods for delivering lipid nanoparticles (LNPs) to a lung cell of a subject suffering from or at risk for primary ciliary dyskinesia (PCD), wherein the method comprises nebulizing a liquid pharmaceutical composition to generate an aerosolized pharmaceutical composition, and administering the aerosolized pharmaceutical composition to the subject.

Compounds of formula (I)wherein A, R, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

There are disclosed phenethylamine compounds, the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor, pharmaceutical compositions such as tablet compositions and kits containing the compounds, methods of delivering the compounds in a mist via inhalation, and methods of treating diseases or disorders associated with a serotonin 5-HT2 receptor, such as central nervous system (CNS) disorders or psychological disorders with the disclosed compounds.

The disclosure relates to a particulate composition comprising ensifentrine, wherein the particulate composition further comprises: from greater than 0.00 wt % to 0.60 wt % of 1,3-bis(2-(2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6, 1-a]isoquinolin-3(4H)-yl)ethyl)urea (BMIQU) relative to the total weight of ensifentrine; and from 0.00 wt % to 0.50 wt % of a biuret impurity of formula (A) relative to the total weight of ensifentrine. Further disclosed herein are liquid pharmaceutical compositions comprising the particulate composition, and a process 10 for producing the particulate composition are also described.

The present invention relates to a process for producing a sterile liquid pharmaceutical composition suitable for administration by inhalation comprising ensifentrine particles, wherein the process comprises: (a) heating ensifentrine particles at a temperature of from 100° C. to 220° C. to obtain sterile ensifentrine particles; and (b) combining the sterile ensifentrine particles with a sterile liquid vehicle to produce the sterile liquid pharmaceutical composition suitable for administration by inhalation. A process for producing an ampule comprising the sterile liquid pharmaceutical composition is also described.

The invention includes methods of preventing or treating acute lung injury using a MAP3K2 / MAP3K3 inhibitor. The invention further comprises compositions, and kits comprising compositions useful within the invention.

Disclosed herein include methods, compositions, and kits suitable for use in preventing or relieving side effects associated with the administration of a weight loss medication. The method can comprise administering to a subject under a weight loss treatment a composition comprising a neurokinin 1 receptor (NK1R) antagonist (e.g., aprepitant).

Provided herein are compositions comprising caveolin-1 (Cav-1) peptides. Further provided are methods of using the Cav-1 peptides for the treatment of lung infections or acute or chronic lung injury, particularly lung fibrosis.

Pharmaceutical compositions comprising epinephrine, methods of administration, and methods of making the same. Compositions may comprise at least one of an active agent, a pH raising agent, an antioxidant, a transition metal complexing agent, a pH lowering agent, a tonicity regulating agent, optionally a preservative, and optionally a solvent.

The invention discloses a refenasin triphenyl acetate and an inhalation powder inhalation thereof. The refenasin triphenyl acetate can be prepared into inhalation powder inhalation, has the effects of good preparation stability, high deposition proportion in an effective part in a body, good curative effect and low side effect, and provides a new drug choice for treatment of COPD patients.

The inhalation suspension preparation containing the SGC receptor stimulant comprises the SGC receptor stimulant with an effective therapeutic dose or pharmaceutically acceptable salt of the SGC receptor stimulant, and pharmaceutically acceptable auxiliary materials of the suspension preparation, the pharmaceutically acceptable auxiliary materials of the suspension preparation comprise at least one of a surfactant, a pH regulator, an osmotic pressure regulator and a metal complexing agent; the inhalation suspension preparation containing the riociguat shows good lung absorption efficiency, is beneficial to reaching the same or better treatment level by reducing the administration dosage, can directly act on a diseased region through an administration route, takes effect more quickly compared with oral administration of the riociguat, and has a good application prospect. Gastrointestinal discomfort and systemic hypotension side effects caused by gastrointestinal tract contact and absorption entering a circulatory system can be avoided, the treatment cycle of an oral dosage form dosage titration administration scheme is shortened, and a better treatment scheme is provided for relieving dyspnea and syncope symptoms of pulmonary hypertension patients treated at home.

Provided herein are compositions comprising caveolin-1 (Cav-1) peptides. Further provided are methods of using the Cav-1 peptides for the treatment of lung infections or acute or chronic lung injury, particularly lung fibrosis.

The present invention relates to a pharmaceutical composition of a tricyclic PDE3 / PDE4 dual inhibitor compound and a method for preparing the same, and more particularly to a pharmaceutical composition of the compound of formula (I) or a pharmaceutically acceptable salt thereof, a method for preparing the same and uses thereof. TIFF2023512475000019.tif40170

Preparation of cannabinoid formulations containing: Δ9-tetrahydrocannabinol (Δ9-THC), Δ8-tetrahydrocannabinol (Δ8-THC), Δ9-tetrahydrocannabinolic acid (THCa), cannabidiol (CBD), cannabidiolic acid (CBDa), cannabigero (CBG), cannabichromene (CBC) and cannabinol (CBN), either alone or in combinations henceforth known as cannabis, have been created using an emulsification process to encapsulate cannabinoids. The aqueous-based method involves micellular encapsulation of cannabinoids, a method that has been used to increase the bioavailability of poorly permeable, lipophilic drugs. The present invention demonstrates the viability of transdermal delivery with gels and patches for consistent and sustained cannabinoid dosing.

Disclosed is a cationic lipid compound of formula (A).Provided herein is a cationic lipid that can be used for the delivery and expression of mRNA and encoded protein, for example, as a component of liposome delivery vehicle, and therefore can be useful for the treatment of various diseases, disorders and conditions, such as those related to one or more protein deficiencies. TIFF2022537580000382.tif4575

Disclosed herein are kits and methods for treating pulmonary arterial hypertension (PAH), comprising administering to a subject in need thereof: •a therapeutically effective amount of a tyrosine kinase inhibitor or a pharmaceutically acceptable salt thereof; and•a therapeutically effective amount of a dimeric fusion protein comprising: •the extracellular domain of the activin type 2A (ACTR IIA) or the activin type 2B receptor (ACTR IIB); and the Fc domain of human immunoglobulin G1 (IgG1). In some embodiments, the tyrosine kinase inhibitor is Seralutinib or a pharmaceutically acceptable salt thereof and the fusion protein is Sotatercept.

The present invention relates to a novel ionizable lipid compound represented by formula (I), or a salt thereof, and lipid nanoparticles comprising same. The lipid nanoparticles comprising the novel ionizable lipid compound, according to the present invention, have excellent nucleic acid encapsulation efficiency and high nucleic acid cell delivery efficiency.

The present invention relates to a method for treating or preventing pathogenic infections in a subject having Cystic Fibrosis, COPD, and / or an open wound. This method involves selecting a subject having Cystic Fibrosis, COPD, and / or an open wound and administering to the selected subject a ceramidase under conditions effective to reduce ceramide and to treat or prevent the pathogenic infection. The method also involves the use of a ceramidase in combination with other drugs to reduce infection, reduce ceramide, or improve lung function in Cystic Fibrosis, COPD, and / or open wound patients.

The present invention relates to an atomized inhalable vaccine formulation and a preparation method therefor. The formulation comprises an active ingredient and auxiliary materials. The active ingredient is an antigen protein-expressing recombinant human replication-defective adenovirus at a low concentration. The auxiliary materials include a buffer, a protectant, a stabilizer, a surfactant, and an osmotic pressure regulator. The atomized inhalable vaccine formulation of the present invention can retain the good stability of a human replication-defective adenovirus vector vaccine formulation.

The present invention relates to a process for producing a sterile liquid pharmaceutical composition suitable for administration by inhalation comprising ensifentrine particles, the process comprising: (a) heating the ensifentrine particles at a temperature of from 100° C. to 220° C. to obtain sterile ensifentrine particles; and (b) combining the sterile ensifentrine particles with a sterile liquid vehicle to produce a sterile liquid pharmaceutical composition suitable for administration by inhalation. A process for producing an ampule comprising the sterile liquid pharmaceutical composition is also described.

The application is directed to a method of inhibiting or reducing growth of clinical isolate bacteria comprising contacting the clinical isolate with a composition comprising glutathione, a glutathione derivative, a glutathione conjugate, a pharmaceutically-acceptable salt thereof, or any combination thereof.

To provide compositions and methods for regulating protein production in target cells. [Solution] The compositions and methods disclosed herein can improve diseases associated with protein or enzyme deficiency. The present invention provides, for example, a composition comprising (a) at least one mRNA molecule that is at least partly encoding a functionally secreted polypeptide, and (b) a transport vehicle comprising lipid nanoparticles. The present invention also provides a method for treating a subject deficient in a functional polypeptide, comprising administering a composition comprising (a) at least one mRNA that is at least partly encoding the functionally secreted polypeptide, and (b) a transport vehicle comprising lipid nanoparticles, wherein after administration of the composition, the mRNA is expressed in a target cell to produce the functionally secreted polypeptide.

Provided are compositions and drug delivery systems containing extracellular vesicles from microalgae (MEVs) that are loaded with bioactive cargo. The MEVs are formulated and administered by a variety of routes of administration and have a variety of applications as therapeutics, including as vaccines, as anti-cancer therapeutics, as therapeutics for psychiatric diseases, disorders, and conditions as diagnostics, and other such uses.

The present disclosure relates to toxin-derived delivery constructs, in particular isolated non-naturally occurring delivery constructs, for oral delivery, comprising a bacterial toxin-derived delivery construct coupled to a biologically active therapeutic cargo; wherein the delivery construct is capable of delivering a bioactive cargo through epithelial cells via endocytotic transport; and wherein the delivery construct does not comprise a bacterial toxin-derived translocation domain or a bacterial toxin-derived catalytic (cytotoxic) domain.

The present disclosure relates to degradable polymers which contain a hydrophobic and hydrophilic segment which is sensitive to pH. In some aspects, the polymers form a micelle which is sensitive to pH and have backbones which are capable of undergoing degradation in vivo. In some aspects, the disclosure also provides methods of using these degradable polymers for the delivery of a drug.

The present application belongs to the technical field of pharmaceutical preparation, and relates to an electrolytic silver ion solution capable of completely inactivating HIV and a preparation method thereof. The electrolytic silver ion solution uses ultrapure water as a solvent, and contains divalent silver ions, a complexing agent and a complexing agent in the electrolytic silver ion solution. The complexing agent is hexamethylenetetramine capable of forming a stable complex with silver ions and capable of quantitatively analyzing the concentration of silver ions. The hexamethylenetetramine is of an analytical purity grade. The complexing agent is ethylenediamine capable of forming a more stable silver-ammonia complex ion, i.e., diammine silver, and capable of doubling the concentration of the generated silver-ammonia complex ion. The concentration of the divalent silver ions is 200-300 mg.kg ‑1 -1; the highest concentration of the complexing agent is 0.9 g.kg ‑1 -1; and the highest concentration of the complexing agent is 0.55 g.kg ‑1 The complexing agent and the complexing agent of the present application have a small dosage, a high relative ratio of silver ions and a stronger activity, and the inactivation rate of HIV is as high as 99.993%.

The invention provides a lung tissue sustained and controlled release material loaded with BMP4 and GANT61 and a preparation method of the lung tissue sustained and controlled release material, and relates to the technical field of disease treatment and delivery materials. The invention relates to a preparation method of a lung tissue sustained and controlled release material loaded with BMP4 and GANT61. The preparation method comprises the following steps: synthesizing HPG by adopting an anionic ring-opening polymerization method; the preparation method comprises the following steps: mixing HPG with PLA, and reacting to prepare a copolymer PLA-HPG; the copolymer PLA-HPG and GANT61 are blended and subjected to a reaction, and nano particles loaded with GANT61 are prepared; and the GANT61-loaded nano particles and BMP4 are subjected to a mixed reaction, such that the BMP4 and GANT61-loaded lung tissue sustained and controlled release material is prepared. The invention constructs a lung tissue sustained and controlled release material loaded with BMP4 and GANT61, and verifies that the lung tissue sustained and controlled release material can realize an anti-pulmonary fibrosis treatment strategy by inducing alpha-SMA + myofibroblast transdifferentiation, resisting inflammation, resisting oxidation and other multiple targets.